Cytokinetics (CYTK) FY2018 results: revenue $32 million, up 135.6% on the year
Cytokinetics Inc. (CYTK) reported revenue of $32 million for fiscal 2018, the year ended 31 December 2018, up 135.6% on the year before. Net income was -$106 million, and diluted earnings per share $-1.95. The figures are the company's own, from the 10-K it filed with the SEC on 7 March 2019.
Revenue
$32 million
+135.6% on the year
FY2011FY2018
Operating margin
-282.3%
-848.3% a year earlier
FY2011FY2018
Net income
-$106 million
FY2011FY2018
Diluted EPS
-$1.95
FY2011FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
31.5
13.4
106
+135.6%
Research and development
89.1
90.3
59.9
-1.3%
Operating income
-88.9
-113
18.7
Operating margin
-282.3%
-848.3%
17.6%
Interest expense
3.8
3.0
2.7
+25.9%
Pre-tax income
-106
-128
16.5
Income tax
0.0
0.0
0.0
Effective tax rate
n/a
n/a
0.0%
Net income
-106
-128
16.5
Net margin
-337.4%
-955.9%
15.5%
Diluted EPS
-$1.95
-$2.59
$0.39
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-101
-102
37.0
Capital expenditure
0.9
2.9
1.6
-69.1%
Free cash flow
-102
-105
35.4
Free cash flow margin
-324.1%
-782.7%
33.3%
Cash from investing
5.1
-65.8
n/a
Cash from financing
13.1
226
n/a
-94.2%
Depreciation and amortisation
1.2
1.9
0.7
-35.5%
Share-based compensation
9.8
9.0
7.1
+8.1%
Diluted shares, weighted
n/a
49m
43m
Shares outstanding at period end
55m
54m
41m
+1.4%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
25.9
110
94.4
-76.4%
Debt
42.4
31.8
29.9
+33.5%
Operating lease liabilities
0.8
n/a
n/a
Other liabilities
142
153
45.9
-7.3%
Total liabilities and equity
211
295
170
-28.4%
Fixed assets
3.2
3.6
3.6
-10.2%
Investments
156
160
97.0
-2.3%
Cash and equivalents
42.3
125
66.9
-66.3%
Receivables
2.2
1.1
0.0
+100.6%
Other assets
7.0
4.7
2.6
+48.5%
Total assets
211
295
170
-28.4%
10-K for the year ended 31 December 2018, filed 7 March 2019: the filing.